Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASE1 | P07998 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | TK2 | O00142 | 4/20 | 0.36 |
| ▸ | PRKCA | P17252 | 5/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA5A | P35218 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.31 |
| ▸ | THRA | P10827 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17230947 | 0.94 | RNASE1 (0.38) | RNASE1SLC6A2TK2PRKCACA12 | |
| SCHEMBL17231038 | 0.88 | RNASE1 (0.38) | RNASE1SLC6A2TK2PRKCACA12 | |
| SCHEMBL20987601 | 0.86 | RNASE1 (0.41) | RNASE1SLC6A2 | |
| SCHEMBL29703141 | 0.86 | TK2 (0.39) | TK2 | |
| SCHEMBL17231013 | 0.84 | RNASE1 (0.39) | RNASE1SLC6A2TK2CA12CA5A | |
| SCHEMBL17230917 | 0.83 | RNASE1 (0.32) | RNASE1TK2PRKCA | |
| SCHEMBL19565366 | 0.80 | TOP2A (0.32) | TK2THRATHRB | |
| SCHEMBL17230822 | 0.79 | TYMP (0.32) | RNASE1 | |
| SCHEMBL20987564 | 0.77 | RNASE1 (0.32) | RNASE1 | |
| SCHEMBL22472268 | 0.76 | RNASE1 (0.51) | RNASE1SLC6A2TK2CA12CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150315229-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315229-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | POLM, POLRMT, RNMT | RNASE1 121/4885SLC6A2 3978/4885TK2 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.